Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFWPLQ)

Drug Name

MEDI-565 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Gastrointestinal cancer	2C11	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting T-cell surface glycoprotein CD3 gamma (CD3G)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tebentafusp	DMUJ1WV	Gastric cancer	2B72	Approved	[3]
Teplizumab	DMZ3P6C	Type-1 diabetes	5A10	Approved	[4]
Ertumaxomab	DM5Z3VP	Breast cancer	2C60-2C65	Phase 2	[5]
MGD007	DMAHWLR	Colorectal cancer	2B91.Z	Phase 1/2	[2]
MT-110	DMPCUN5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
Autologous T-cell therapy	DMOAET3	Prostate cancer	2C82.0	Phase 1	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell surface glycoprotein CD3 gamma (CD3G)	TTV3XPL	CD3G_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01284231) A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas. U.S. National Institutes of Health.
2	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
6	EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
7	Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.